IAG:NYSEIamgold Corporation Analysis
Data as of 2026-05-20 - not real-time
$16.18
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
IAMGOLD trades at $16.18, barely above the technical support of $16.03 and well below the 200‑day SMA of $15.64, suggesting limited upside on the chart in the near term. The stock’s RSI of 37 and a bearish MACD histogram point to short‑term weakness, but the price remains far under the DCF‑derived fair value of $59.25, implying a potential upside of over 60% based on fundamentals. Earnings guidance shows a dramatic 420% Q1 earnings surge, driven by a production of 183,600 ounces and robust gold prices, while operating margins sit at a healthy 52.8% and ROE is near 28%, underscoring strong profitability. The company’s balance sheet features $551 M cash against $651 M debt, a moderate leverage profile, and free cash flow of $972 M, supporting continued growth and shareholder returns. Analyst consensus is a “Buy” with a median target of $25, reflecting confidence in the long‑run trajectory despite current technical headwinds. The sector’s gold exposure benefits from the current “Extreme Greed” sentiment in the market, and hedge funds have highlighted IAG as a top pick, adding credibility to the upside narrative. Overall, the fundamentals are compelling while the price remains deeply discounted, making the stock a high‑conviction opportunity for investors with a longer horizon.
In the short term, traders should watch the $16.03 support and the $19.59 resistance, as a breach either way could trigger a swing. Medium‑ to long‑term investors can capitalize on the valuation gap, strong cash generation, and favorable commodity dynamics, positioning IAG as a potentially rewarding addition to a diversified portfolio.
In the short term, traders should watch the $16.03 support and the $19.59 resistance, as a breach either way could trigger a swing. Medium‑ to long‑term investors can capitalize on the valuation gap, strong cash generation, and favorable commodity dynamics, positioning IAG as a potentially rewarding addition to a diversified portfolio.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering just above technical support
- Bearish MACD and neutral RSI indicating limited near‑term momentum
- Decreasing volume suggesting lower short‑term participation
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Projected 420% earnings growth and strong production ramp‑up
- DCF fair value indicating >60% upside
- Robust operating margins and high ROE supporting earnings expansion
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Fundamental undervaluation relative to fair value
- Sustained cash flow generation and manageable debt levels
- Long‑term gold price tailwinds and sector positioning as a defensive asset
Key Metrics & Analysis
Financial Health
Revenue Growth115.90%
Profit Margin29.49%
P/E Ratio9.5
ROE27.96%
ROA16.90%
Debt/Equity14.71
P/B Ratio2.2
Op. Cash Flow$1.6B
Free Cash Flow$971.6M
Technical Analysis
TrendNeutral
RSI37.0
Support$16.03
Resistance$19.59
MA 20$17.43
MA 50$18.33
MA 200$15.64
MACDBearish
VolumeDecreasing
Fear & Greed Index89.18
Valuation
Fair Value$59.25
Target Price$26.30
Upside/Downside62.55%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.52
Volatility62.96%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.